Farmaceutica, Runggaldier (Novartis Italy): “R&D are the soul of the company”

“Research and development are the soul of Novartis, and it is no coincidence that it ranks among the pharmaceutical companies most committed to innovation, at the top of clinical research, against investments of 66 million euros and 238 clinical studies , according to 2020 data “. This was stated by Eva J. Runggaldier, Country Head of Trial Monitoring of Novartis, on the occasion of Breakthrough Science, an event promoted by the Swiss giant and which was held today at Havas Village Italia in Milan. According to Runggaldier, “a further growth opportunity comes from the new EU Regulation 536/2014 for clinical trials, whose approval is expected in 2022. The text aims to increase the competitiveness of the European Union and its level of innovation, simplifying the several approval steps. ”A rationalization“ of the bureaucracy which, especially in Italy, represents a fundamental element to be able to be more competitive at international level in this sector ”, concluded Runggaldier.